For AI to be transformative in the pharmaceutical industry, it must be designed with a security-first approach. This means ...

The transition from writing to programming regulatory submissions represents one of the most significant efficiency ...

Finding a conversation about AI at a conference like BIO 2025 is easy. But making those conversations meaningful and asking ...

AstraZeneca chief executive Pascal Soriot is considering moving the company's stock exchange listing from the UK to the US – ...

According to the government, the passport will eliminate multiple compliance assessments, reducing duplication across the ...

The One Big Beautiful Bill (BBB), which passed (PDF) by a 51-50 vote with Vice President JD Vance casting the tie-breaker, ...

Basel-based BioVersys stands to receive CHF 5 million upfront under the terms of the deal, which could be worth up to CHF 479 ...

The 7th Exosome-Based Therapeutics Development Summit with never-before-seen data, covering the end-to-end from discovery ...

Cosmo Feilding Mellen – currently Beckley's chief executive, who is slated to serve as chief strategy officer of the merged ...

Touchstone and Rowley highlight why companies like Eli Lilly, Novo Nordisk, and Genentech are choosing to set up shop in ...

In the case of the amyloid drugs, Eisai Biogen's Leqembi (lecanemab) and Eli Lilly's Kisunla (donanemab) – there are also ...

The next frontier in clinical development is modelling feasibility and continuous scenario-planning, even amid changing ...